



PC-218-T025

## Monoclonal Antibody to CD25 PerCP (25 tests)

Clone: MEM-181

Isotype: Mouse IgG1

**Specificity:** The antibody MEM-181 reacts with CD25 (Interleukin-2 receptor alpha chain), a 55

kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4+ T lymphocytes (T

regulatory cells); it is lost on resting B and T lymphocytes.

HLDA VI; WS Code NL N-L024

Regulatory Status: RUO

Immunogen: PHA-activated peripheral blood leucocytes

Species Reactivity: Human

**Preparation:** The purified antibody is conjugated with Peridinin-chlorophyll-protein complex

(PerCP) under optimum conditions. The conjugate is purified by size-exclusion

chromatography and adjusted for direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

**Storage / Stability:** Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using

10 µl reagent / 100 µl of whole blood or 10<sup>6</sup> cells in a suspension.

The content of a vial (0.25 ml) is sufficient for 25 tests.

Expiration: See vial label

Lot Number: See vial label

Background: CD25 (IL2Ralpha, Tac) is a ligand-binding alpha subunit of interleukin 2 receptor

(IL2R). Together with beta and gamma subunit CD25 constitues the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. Humanized anti CD25 antibodies represent a useful tool to reduce the incidence of allograft rejection as well as the severity of graft versus host reaction, and radioimmunoconjugates of anti-CD25 antibodies can be used against CD25

expressing lymphomas.



## PRODUCT DATA SHEET

## References:

\*Lai KN, Leung JC, Lai FM: Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T-lymphocytes in vitro. Pathology. 1991 Jul;23(3):224-8.

\*Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75). Res Immunol. 1992 Jan;143(1):33-7.

\*Morris JC, Waldmann TA: Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis. 2000 Nov;59 Suppl 1:i109-14.

\*Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004 Oct;28(10):1319-25.

\*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997). \*Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single-molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int Immunol. 2007 May;19(5):675-84.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.